The treatment of renal cell carcinoma has long been dominated by targeted treatments, including mTOR and angiogenesis inhibitors. However, the introduction of immune checkpoint inhibitors has diversified treatment options. The treatment landscape for renal cell carcinoma is rapidly moving toward combination combinatorial approaches, as witnessed by the approvals of Lenvima/Kisplyx (Eisai) plus Afinitor (Novartis) in 2016, Opdivo plus Yervoy (Bristol-Myers Squibb/Ono Pharmaceutical) in 2018, and Keytruda (Merck & Co.) plus Inlyta (Pfizer) in 2019. As combination regimens experience uptake in the larger and more commercially lucrative first-line advanced setting, drug developers should gain an understanding of the key drivers and obstacles to maximize uptake.

Questions Answered

  • What are the drug-treatment rates across clinically and commercially relevant renal cell carcinoma patient populations?
  • How are the new drug entrants performing in the face of existing small-molecule TKIs such as Votrient and Sutent for advanced disease?
  • What is the uptake of Opdivo plus Yervoy in previously untreated intermediate- or poor-risk advanced renal cell carcinoma, according to U.S. medical oncologists?
  • What factors drive or constrain the prescribing habits of U.S. medical oncologists?

Product Description

Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Geographies: United States

Primary Research: Survey of 100 medical oncologists in the United States

Key Ddrugs Ccovered: Opdivo, Yervoy, Cabometyx, Sutent, Votrient, Inlyta, Afinitor, Lenvima

Related Reports

Renal Cell Carcinoma - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (US) 2020

This report is available to find out more click the link and fill out the form to get more details.

View Details

Renal Cell Carcinoma - Current Treatment - Detailed, Expanded Analysis (US)

The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the management of this disease. In a landscape previously dominated by mTOR and angi...

View Details

Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast

Building on the success of the PD-1 inhibitor Opdivo (Bristol Myers Squibb / Ono Pharmaceutical) in the recurrent renal cell carcinoma setting, combination regimens, including Opdivo plus Yervoy, K...

View Details

Renal Cell Carcinoma - Epidemiology - Mature Markets

DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across the major mature pharmace...

View Details